FreeGuest Editorial The global health contributions of Norm Coleman March 22, 2024Vol.50 No.12By Nina Wendling and Donna M. O’Brien
Drugs & Targets Tempus contributes de-identified cancer data to NCI’s planned data enclave March 22, 2024Vol.50 No.12
White House Biden’s FY25 budget requests $522M increase for NCI, $1.5B for ARPA-H, $2.9B for Moonshot March 15, 2024Vol.50 No.11By Alexandria Carolan
In Brief Rutgers Cancer Institute redesignated as NCI Comprehensive Cancer Center March 08, 2024Vol.50 No.10
In Brief President’s Cancer Panel recommends five priority areas for the National Cancer Plan March 01, 2024Vol.50 No.09
Drugs & Targets Lixte Biotechnology enters exclusive immuno-oncology patent license agreement with NINDS, NCI March 01, 2024Vol.50 No.09
First-ever commercial TIL therapy: How NCI, Iovance, and Moffitt achieved FDA approval February 23, 2024Vol.50 No.08By Matthew Bin Han Ong
Conversation with The Cancer Letter Steven Rosenberg, Friedrich Graf Finckenstein: FDA recognition of TIL therapy is the result of 40 years of research February 23, 2024Vol.50 No.08By Matthew Bin Han Ong
Clinical Roundup NCI launches research network to evaluate emerging cancer screening technologies February 23, 2024Vol.50 No.08
